Atara Biotherapeutics (ATRA) Other Gross PP&E Adjustments (2022 - 2025)
Atara Biotherapeutics (ATRA) has disclosed Other Gross PP&E Adjustments for 4 consecutive years, with -$10.2 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Other Gross PP&E Adjustments rose 61.13% year-over-year to -$10.2 million, compared with a TTM value of -$10.2 million through Sep 2025, up 61.13%, and an annual FY2024 reading of -$27.0 million, up 45.18% over the prior year.
- Other Gross PP&E Adjustments was -$10.2 million for Q3 2025 at Atara Biotherapeutics, up from -$10.5 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $427000.0 in Q1 2022 and bottomed at -$68.5 million in Q4 2022.
- Average Other Gross PP&E Adjustments over 4 years is -$35.7 million, with a median of -$39.6 million recorded in 2023.
- The sharpest move saw Other Gross PP&E Adjustments crashed 10879.86% in 2023, then soared 64.16% in 2025.
- Year by year, Other Gross PP&E Adjustments stood at -$68.5 million in 2022, then grew by 28.11% to -$49.2 million in 2023, then surged by 45.18% to -$27.0 million in 2024, then soared by 62.38% to -$10.2 million in 2025.
- Business Quant data shows Other Gross PP&E Adjustments for ATRA at -$10.2 million in Q3 2025, -$10.5 million in Q2 2025, and -$48.8 million in Q1 2025.